iXgene Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
12
iXgene General Information
Description
Developer of a regenerative medicine intended for brain tumors and injury. The company focuses on migrating and accumulating brain tumors and brain-damaged areas, neural stem cells that differentiate into iPS cells with suicide gene suicide genes, enabling healthcare sectors and patients to reduce the activation of suicide genes and provide treatment of brain diseases using suicide transgenic iPS cell-derived neural stem cells.
Contact Information
Website
www.ixgene.incCorporate Office
- 1-14-1 Yotsuya
- Shinjuku-ku
- Tokyo, 160-0004
- Japan
Corporate Office
- 1-14-1 Yotsuya
- Shinjuku-ku
- Tokyo, 160-0004
- Japan
iXgene Timeline
iXgene Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | 03-Sep-2025 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 29-Oct-2024 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 01-Mar-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 05-Jan-2023 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2021 | Completed | Startup | |||
| 2. Seed Round | 01-Oct-2020 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
iXgene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
iXgene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
iXgene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
iXgene Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MEDISO | Accelerator/Incubator | |||
| J-StarX | Accelerator/Incubator | |||
| Japan External Trade Organization | Accelerator/Incubator | |||
| LINK-J | Accelerator/Incubator | |||
| Green Core | Venture Capital | Minority |
iXgene FAQs
-
When was iXgene founded?
iXgene was founded in 2020.
-
Where is iXgene headquartered?
iXgene is headquartered in Tokyo, Japan.
-
What is the size of iXgene?
iXgene has 10 total employees.
-
What industry is iXgene in?
iXgene’s primary industry is Drug Discovery.
-
Is iXgene a private or public company?
iXgene is a Private company.
-
What is iXgene’s current revenue?
The current revenue for iXgene is .
-
How much funding has iXgene raised over time?
iXgene has raised $4.47M.
-
Who are iXgene’s investors?
MEDISO, J-StarX, Japan External Trade Organization, LINK-J, and Green Core are 5 of 12 investors who have invested in iXgene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
